216 related articles for article (PubMed ID: 29490634)
1. A novel canine histiocytic sarcoma cell line: initial characterization and utilization for drug screening studies.
Takada M; Parys M; Gregory-Bryson E; Vilar Saavedra P; Kiupel M; Yuzbasiyan-Gurkan V
BMC Cancer; 2018 Mar; 18(1):237. PubMed ID: 29490634
[TBL] [Abstract][Full Text] [Related]
2. Development of an Orthotopic Intrasplenic Xenograft Mouse Model of Canine Histiocytic Sarcoma and Its Use in Evaluating the Efficacy of Treatment with Dasatinib.
Takada M; Smyth LA; Hix JM; Corner SM; Kiupel M; Yuzbasiyan-Gurkan V
Comp Med; 2019 Feb; 69(1):22-28. PubMed ID: 30717820
[TBL] [Abstract][Full Text] [Related]
3. Effect of dasatinib in a xenograft mouse model of canine histiocytic sarcoma and in vitro expression status of its potential target EPHA2.
Ito K; Miyamoto R; Tani H; Kurita S; Kobayashi M; Tamura K; Bonkobara M
J Vet Pharmacol Ther; 2018 Feb; 41(1):e45-e48. PubMed ID: 28833247
[TBL] [Abstract][Full Text] [Related]
4. Identification of dasatinib as an in vitro potent growth inhibitor of canine histiocytic sarcoma cells.
Ito K; Kuroki S; Kobayashi M; Ono K; Washizu T; Bonkobara M
Vet J; 2013 Jun; 196(3):536-40. PubMed ID: 23369384
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the drug sensitivity and expression of 16 drug resistance-related genes in canine histiocytic sarcoma cell lines.
Asada H; Tomiyasu H; Goto-Koshino Y; Fujino Y; Ohno K; Tsujimoto H
J Vet Med Sci; 2015 Jun; 77(6):677-84. PubMed ID: 25715778
[TBL] [Abstract][Full Text] [Related]
6. Multifocal cutaneous histiocytic sarcoma in a young dog and review of histiocytic cell immunophenotyping.
Mastrorilli C; Spangler EA; Christopherson PW; Aubry OA; Newton JC; Smith AN; Kennis RA; Weismann JL; Moore PF
Vet Clin Pathol; 2012 Sep; 41(3):412-8. PubMed ID: 22747712
[TBL] [Abstract][Full Text] [Related]
7. Targeting MEK in a Translational Model of Histiocytic Sarcoma.
Takada M; Hix JML; Corner S; Schall PZ; Kiupel M; Yuzbasiyan-Gurkan V
Mol Cancer Ther; 2018 Nov; 17(11):2439-2450. PubMed ID: 30135215
[TBL] [Abstract][Full Text] [Related]
8. Survivin suppressor (YM155) enhances chemotherapeutic efficacy against canine histiocytic sarcoma in murine transplantation models.
Yamazaki H; Takagi S; Hosoya K; Okumura M
Res Vet Sci; 2015 Apr; 99():137-44. PubMed ID: 25744435
[TBL] [Abstract][Full Text] [Related]
9. Localized and disseminated histiocytic sarcoma of dendritic cell origin in dogs.
Affolter VK; Moore PF
Vet Pathol; 2002 Jan; 39(1):74-83. PubMed ID: 12102221
[TBL] [Abstract][Full Text] [Related]
10. Apoptosis inhibitor of macrophage (AIM) reduces cell number in canine histiocytic sarcoma cell lines.
Uchida M; Saeki K; Maeda S; Tamahara S; Yonezawa T; Matsuki N
J Vet Med Sci; 2016 Oct; 78(9):1515-1520. PubMed ID: 27246397
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of a combination chemotherapy protocol including lomustine and doxorubicin in canine histiocytic sarcoma.
Cannon C; Borgatti A; Henson M; Husbands B
J Small Anim Pract; 2015 Jul; 56(7):425-9. PubMed ID: 25828786
[TBL] [Abstract][Full Text] [Related]
12. Bisphosphonates significantly increase the activity of doxorubicin or vincristine against canine malignant histiocytosis cells.
Hafeman SD; Varland D; Dow SW
Vet Comp Oncol; 2012 Mar; 10(1):44-56. PubMed ID: 22236140
[TBL] [Abstract][Full Text] [Related]
13. Utility of the second-generation curcumin analogue RL71 in canine histiocytic sarcoma.
Kelly B; Thamm D; Rosengren RJ
Vet Res Commun; 2024 Feb; 48(1):563-568. PubMed ID: 37597087
[TBL] [Abstract][Full Text] [Related]
14. Passage-dependent morphological and phenotypical changes of a canine histiocytic sarcoma cell line (DH82 cells).
Heinrich F; Contioso VB; Stein VM; Carlson R; Tipold A; Ulrich R; Puff C; Baumgärtner W; Spitzbarth I
Vet Immunol Immunopathol; 2015 Jan; 163(1-2):86-92. PubMed ID: 25534080
[TBL] [Abstract][Full Text] [Related]
15. Intratumoral Canine Distemper Virus Infection Inhibits Tumor Growth by Modulation of the Tumor Microenvironment in a Murine Xenograft Model of Canine Histiocytic Sarcoma.
Armando F; Fayyad A; Arms S; Barthel Y; Schaudien D; Rohn K; Gambini M; Lombardo MS; Beineke A; Baumgärtner W; Puff C
Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33808256
[TBL] [Abstract][Full Text] [Related]
16. RNA in situ hybridisation as a molecular diagnostic technique targeting IBA-1 and CD204 in canine histiocytic sarcoma.
Engelien JL; Lejeune AT; Dark MJ; Milner RJ; Shiomitsu K
Vet Med Sci; 2022 Jul; 8(4):1400-1408. PubMed ID: 35339118
[TBL] [Abstract][Full Text] [Related]
17. Influence of a survivin suppressor YM155 on the chemoresistance of canine histiocytic sarcoma cells.
Yamazaki H; Takagi S; Hosoya K; Okumura M
Vet J; 2015 Sep; 205(3):375-80. PubMed ID: 26048444
[TBL] [Abstract][Full Text] [Related]
18. Variations in Histiocytic Differentiation of Cell Lines From Canine Cerebral and Articular Histiocytic Sarcomas.
Thongtharb A; Uchida K; Chambers JK; Nakayama H
Vet Pathol; 2017 May; 54(3):395-404. PubMed ID: 28178429
[TBL] [Abstract][Full Text] [Related]
19. Epirubicin in the treatment of canine histiocytic sarcoma: sequential, alternating and rescue chemotherapy.
Mason SL; Finotello R; Blackwood L
Vet Comp Oncol; 2018 Mar; 16(1):E30-E37. PubMed ID: 28621004
[TBL] [Abstract][Full Text] [Related]
20. Clinical prognostic factors in canine histiocytic sarcoma.
Dervisis NG; Kiupel M; Qin Q; Cesario L
Vet Comp Oncol; 2017 Dec; 15(4):1171-1180. PubMed ID: 27334037
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]